patients were stained for iron and TfR1 protein using Prussian Blue and immunohistochemistry, respectively. 178 tissue cores from 14 different body sites of non-cancer patients were included as controls. Staining was scored by a clinically blinded genitourinary pathologist based on the product of intensity and tissue percentage (Z-score), and tested for association with clinicopathologic features and survival using a MannWhitney U test, Kruskal Wallis test and Cox regression model. RESULTS: Renal epithelium from non-cancer patients had low iron content (mean Z-score, MZS¼ 0.1), but by far the highest TfR1 levels of any tissue site in the body (MZS¼ 153). Compared to non-cancer patients, iron content in RCC patients increased mildly (4-fold) in benign renal epithelium (MZS¼ 0.6) and dramatically (>100 fold) in primary tumors (MZS¼ 21, p< 0.001). Higher tumor iron content was accompanied by moderate TfR1 downregulation (MZS¼ 21, p< 0.001) and associated with clear cell and papillary histologies, male gender and tobacco usage (p< 0.05 each). Opposite to changes observed with tumorigenesis, iron and TfR1 levels decreased and increased, respectively, with progression in tumor size, grade, pT stage and metastatic stage (all p< 0.05). Iron loss and TfR1 upregulation were most apparent in metastatic lesions (MZS¼ 5 and 111, respectively) and each associated with patient anemia and worse RCC-specific survival (all p< 0.05).
INTRODUCTION AND OBJECTIVES: Five-year survival of metastatic renal cell carcinoma (mRCC) patients is < 10% and African American (AA) males have the highest incidence. Identification of the molecular determinants of mRCC and racial disparity in RCC is critical for biomarker development and targeted therapy. SDCT2 expressed in kidney epithelial cells is a succinate/citrate transporter, however its role has not been examined in any disease. We examined SDCT2 expression in normal and RCC tissues and correlated it with clinical outcome and racial disparity. We also evaluated biological functions and molecular signaling regulated by SDCT2 in RCC cells.
METHODS: Differential gene expression in the matched normal and RCC tissues (n¼6/category) was evaluated by microarray analysis; results were validated by QPCR and immunoblotting in tissues from 53 patients (White¼21; Hispanic¼19; AA¼13). VHL+ and VHL-RCC cells were stablely transfected with a SDCT2 construct. Transfectants were characterized for cell proliferation, cell cycle, motility, succinate/citrate transport and reactive oxygen species (ROS) measurement assays under normoxia and hypoxia. SDCT2 induction was evaluated following 5-azacytidine plus Trichostatin A (5-AZA/TSA) treatment.
RESULTS: SDCT2 was 63-and 100-fold downregulated in lowand high-stage RCC tissues. Q-PCR validation showed 40-fold downregulation of SDCT2 in RCC tissues when compared to normal kidney (P< 0.0001). Downregulation was 40-fold in White and Hispanic patients, but 198-fold in AA patients (P¼0.0049) and correlated with tumor stage and metastasis (P¼0.009). Under hypoxia, SDCT2 expression caused 3-4-fold inhibition of proliferation, cell-cycle, motility in both VHL+ and VHL-cells (P<0.01); only VHL+ cells were inhibited under normoxia. SDCT2 expression induced ROS levels and succinate transport by >3-fold (P<0.01) and activated p16INK4a-RB pathway and apoptosis (caspase-3 and PARP activation). 5-AZA+TSA treatment induced SDCT2 expression by 50-fold (P<0.001).
CONCLUSIONS: This is the first study on a functional biomarker in RCC, SDCT2, that is possibly a novel tumor suppressor gene. SDCT2 loss promotes RCC growth, survival and inhibits cellular senescence and its downregulation correlates with metastasis and racial disparity.
Source of Funding: Grant NCI/NIH 5R01CA72821; 5R01CA176691
MP39-16 SERUM TISSUE FACTOR AS A BIOMARKER FOR RENAL CLEAR CELL CARCINOMA
Daniel Silva*, Bartira Pinheiro da Costa, Jorge Antonio Pastro Noronha, Gustavo Carvalhal, Porto Alegre, Brazil
INTRODUCTION AND OBJECTIVES:
We have previously demonstrated that increased expression of Tissue Factor (TF) in tissue samples RCCC is an independent prognostic factor of aggressive behavior and of cancer specific mortality. We aimed to compare preoperative serum TF levels in RCCC patients with those of patients submitted to surgical interventions in patients without RCCC. Additionally, to verify the difference in preoperative and postoperative serum TF levels in RCCC patients in blood samples collected before surgery and after at least four weeks of the surgical procedure.
METHODS: We conducted a prospective study of 30 patients with RCCC submitted to either partial or radical nephrectomy and 16 controls without RCCC treated surgically for other conditions. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systemsâ).
RESULTS: Mean preoperative serum TF levels in RCCC patients and in controls were 66.8 pg/dl and 28.4 pg/dl, respectively (p<0.001). Mean postoperative serum TF levels in RCCC patients were 26.3 pg/dl. In all patients with RCCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dl in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (Pearson coefficient ¼ -0.38 ;p¼0.037).
CONCLUSIONS: We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with RCCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of RCCC. Further studies are needed to validate these findings. . 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e499
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MP39-17
MITOCHONDRIAL DNA COPY NUMBER VARIATION AS A POTENTIAL PREDICTOR OF RENAL CELL CARCINOMA.
Eman Elsayed, Mohamed Mohieeldin Hashad*, Eman Elgohary, Alexandria, Egypt INTRODUCTION AND OBJECTIVES: Peripheral blood mitochondrial DNA (mtDNA) is suggested as a risk factor for several types of cancer. Previous studies have assessed the association between mtDNA and renal cell carcinoma (RCC), however, contradictory results were obtained. The aim of the present study was to assess the role of peripheral blood mtDNA in prediction and early detection of renal cell carcinoma in a cohort of Egyptian patients.
METHODS: The study enrolled 57 patients with early localized RCC (TNM stage I and II), confirmed by histopathological examination. They were consecutively recruited between August 2012 and March 2015 after excluding patients with advanced RCC (TNM stage III and IV) (to omit the effect of disease progression on mtDNA content), patients with other malignancies, family history of kidney cancer, recurrent RCC, and patients who received neoadjuvant therapy. Sixty healthy individuals with matching age and sex were included as control. The Ethics Committee approved this study and all subjects gave informed consent.Relative mtDNA copy number was measured using quantitative real-time PCR assay. Mitochondrial DNA (mtDNA) copy number was determined relative to the nuclear gene (HBB gene) using the formula -2DDCt . RESULTS: Fifty seven patients (36 males, 21 females) diagnosed with early localized RCC were included: 50 clear RCC,5 papillary RCC and 2 chromophobe RCC cases. The mean age was 60.14 AE 6.83 years. Median mtDNA copy number was significantly higher in RCC cases than controls (166 vs 91, P<0.001). The role of mtDNA copy number as a risk factor for RCC was evaluated using unconditional logistic regression analysis. The median mtDNA content of the control group (91) was used as a cutoff value to analyze mtDNA copy number. It was found that patients with mtDNA content higher than 91 had a significant increase in RCC risk of 18 fold than those with lower levels with OR (odds ratio) of 18.0 (95% CI ¼ 5.065-63.9) in univariate analysis and an adjusted OR of 18.9 (95% CI ¼ 5.11-70.11) in multivariate analysis (after adjusting for age, gender, smoking status, hypertension and body mass index). The diagnostic value of mtDNA content in early detection of RCC was further assessed. Using receiver operating curve (ROC curve) analysis, it was found that mtDNA can detect RCC at a cutoff value of 108.5 with 86% sensitivity, 80% specificity, 80.3 % positive predictive value and 85.7% negative predictive value.
CONCLUSIONS: Increased mtDNA copy number could be used as a potential independent predictor of RCC risk. In addition, it may serve as a promising non-invasive biomarker for early detection of RCC. METHODS: An increase in the clear cytoplasm caused using adipogenic induction media (Lonza) in Caki-1 and Caki-2 cells. Human PCR array (Qiagen) was conducted for comparison of gene expressions which are related to adipogenesis and mitochondria. Western blotting and confocal microscopy were utilized to observe the protein expressions for mitochondria biogenesis. JC-1 dye staining (Cayman) to measure mitochondrial membrane potential was performed to observe mitochondrial function.
RESULTS: Clear cytoplasm was found to increase more in Caki-1 cells than in Caki-2. The increases of clear cytoplasm in Caki-1 cells were induced up-regulation of adipogenesis-related genes. In particular, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1a) which promotes mitochondrial biogenesis demonstrated an 11-fold increase (Fig. 1A) . This up-regulation of PGC1a genes led increases in genes of voltage-dependent anion channels and cytochrome C oxidase subunit IV, ultimately promoting mitochondrial biogenesis (Fig. 1B, C) . Also, in Caki-1 cells with increased clear cytoplasm, a mitochondrial healthy state was maintained with no impact on membrane potential, which is a significant role of mitochondria for cell's homeostasis ( Fig. 2A) . Such activation of PGC1a was found to be caused by increased phosphorylation of AMPactivated protein kinase (AMPK) (Fig. 2B, C) .
